Voyager Therapeutics Inc(NASDAQ:VYGR) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during Pre-Market on Mar 15, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $2.362M. Analysts estimated a revenue of $4.250M. The revenues were -44.42% below the estimates. Earnings per share were $-0.57. The reported EPS was below estimates by -29.55%. Analysts had estimated an EPS of $-0.44.
In a different note, Nomura said it Initiates Coverage On Voyager Therapeutics Inc, according to a research note issued on Mar 2, 2017. The shares have been rated ‘Buy’ by the firm.
Voyager Therapeutics Inc (VYGR) shares turned negative on Fridays trading session with the shares closing down -0.16 points or -1.42% at a volume of 1,98,113. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $11.26. The peak price level was also seen at $11.26 while the days lowest was $10.71. Finally the shares closed at $11.11. The 52-week high of the shares is $18.25 while the 52-week low is $8.3. According to the latest information available, the market cap of the company is $298 M.
Several Insider Transactions has been reported to the SEC. On Jan 15, 2016, Steven M Paul (CEO) purchased 10,000 shares at $14.07 per share price.
Voyager Therapeutics Inc. is a clinical-stage gene therapy company. The Company focuses on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). Its product engine has generated programs for five CNS indications including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis; Friedreich’s ataxia; Huntington’s disease and spinal muscular atrophy. The Company’s gene therapy approach uses adeno-associated virus (AAV) vectors which are modified non-replicating versions of AAV and which are ideal vectors for CNS gene therapy. It is also focused on gene replacement and gene knockdown approaches. Its products are VY-AADC01 program for advanced Parkinson’s disease VY-SOD101 for a monogenic form of Amyotrophic lateral sclerosis (ALS) VY-FXN01 for Friedreich’s ataxia VY-HTT01 for Huntington’s disease and VY-SMN101 for spinal muscular atrophy (SMA).